What this trial means for you
This study is active, not recruiting — it is not currently taking new participants, but its results may matter for treatments you're considering. It's studying LY3841136, Tirzepatide, Placebo for obesity, overweight.
What participants typically get: study medication (or placebo, if the trial uses one) and study-related medical care at no cost, plus close monitoring. Compensation for time and travel varies by study — ask the site. Note that in many trials you can't choose your treatment group, and some participants receive a placebo.
The study, in the sponsor's words
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate the safety and efficacy of LY3841136 for chronic weight management alone or in combination with Tirzepatide across a wide dose range in participants with Type 2 Diabetes. Participation in the study will last about 64 weeks.
Can you join? The exact criteria
Below is the verbatim eligibility text from the registry — bring it to your doctor; it's written for clinicians, and your own clinician is the right person to interpret it with you.
Full eligibility criteria (for you and your doctor)
Inclusion Criteria: W8M-MC-LAA2 * Have a Body Mass Index (BMI) of ≥27 kilograms per square meter (kg/m²) * Have Type 2 Diabetes * Have a HbA1c ≥7.0 % (53 millimoles/mole (mmol/mol)) to ≤10.5% (91 mmol/mol) and treated with diet and exercise alone or with a stable dose of metformin (and not more than the locally approved dose) with or without a sodium-glucose cotransporter 2 (SGLT2) inhibitor for at least 3 months prior to screening W8M-MC-CWMM: * Have had a stable body weight for the 3 months prior to randomization (\<5% body weight gain and/or loss) Exclusion Criteria: W8M-MC-LAA2 * Have a history of severe hypoglycemia or hypoglycemia unawareness within the last 6 months prior to screening * Have an on-going or history of bradyarrhythmia and/or sinus bradycardia * Have an elevated resting pulse rate (mean \>100 beats per minute (bpm)) or reduced resting pulse rate (mean \<60 bpm) at screening * Have any of the following cardiovascular conditions within 6 months prior to screening: * acute myocardial infarction * cerebrovascular accident (stroke) * unstable angina, or * hospitalization due to congestive heart failure * Have renal impairment measured as estimated glomerular filtration rate (eGFR) \<45 milliliters per minute (mL/min)/1.73 m2 * Have a history of acute or chronic pancreatitis * Have fasting triglycerides \>500 milligrams per deciliter (mg/dL) (5.7 mmol/L) at screening * All concomitant medications should be at a stable dose for at least 3 months prior to screening W8M-MC-CWMM * Have a prior or planned surgical treatment for obesity, except prior liposuction or abdominoplasty, if performed \>1 year prior to screening. * Have type 1 diabetes mellitus, latent autoimmune diabetes in adults, or history of ketoacidosis or hyperosmolar coma. * Have poorly controlled hypertension. * Have a history of symptomatic gallbladder disease within the past 2 years * Have signs and symptoms of any liver disease other than nonalcoholic fatty liver disease. * Have a lifetime history of suicide attempts.
Study sites by state
Arizona
- The Institute for Liver Health II dba Arizona Clinical Trials - Mesa — Chandler
- HOPE Research Institute — Phoenix
- Headlands Research - Scottsdale — Scottsdale
- The Institute for Liver Health II dba Arizona Liver Health-Tucson — Tucson
California
- NorCal Medical Research, Inc — Greenbrae
- Velocity Clinical Research, Huntington Park — Huntington Park
- Peninsula Research Associates — Rolling Hills Estates
- Diablo Clinical Research, Inc. — Walnut Creek
Connecticut
- Stamford Therapeutics Consortium — Stamford
Florida
- Northeast Research Institute (NERI) — Fleming Island
- Indago Research & Health Center, Inc — Hialeah
- New Horizon Research Center — Miami
- Suncoast Clinical Research, Inc. — New Port Richey
- Charter Research - Winter Park — Orlando
- Charter Research - Lady Lake — The Villages
Idaho
- Medical Research Partners — Ammon
Illinois
- Great Lakes Clinical Trials - Andersonville — Chicago
- Great Lakes Clinical Trials - Ravenswood — Chicago
- NorthShore University Health System — Skokie
Iowa
- Iowa Diabetes and Endocrinology Research Center — West Des Moines
Kansas
- Cotton O'Neil Diabetes & Endocrinology — Topeka
Massachusetts
- Knownwell — Needham
- Lucida Clinical Trials — New Bedford
Michigan
- Headlands Research - Detroit — Southfield
- Arcturus Healthcare , PLC, Troy Internal Medicine Research Division — Troy
Missouri
- StudyMetrix Research — City of Saint Peters
- Clinvest Headlands Llc — Springfield
Nevada
- Las Vegas Medical Research — Las Vegas
New York
- Dent Neurologic Institute — Amherst
- Velocity Clinical Research, Syracuse — East Syracuse
- North Suffolk Neurology — Port Jefferson Station
- Rochester Clinical Research, LLC — Rochester
North Carolina
- Medication Management — Greensboro
- Monroe Biomedical Research — Monroe
- Lucas Research, Inc — Morehead City
- Lucas Research, Inc. — New Bern
Ohio
- CTI Clinical Research Center — Cincinnati
South Carolina
- Tribe Clinical Research, LLC — Greenville
Tennessee
- Quality Medical Research — Nashville
Texas
- IMA Clinical Research Austin — Austin
- Velocity Clinical Research, Dallas — Dallas
- FutureSearch Trials of Dallas — Dallas
- PlanIt Research, PLLC — Houston
- Tekton Research - Fredericksburg Road — San Antonio
- Endeavor Clinical Trials — San Antonio
- Texas Valley Clinical Research — Weslaco
Virginia
- Spectrum Medical, Inc. — Danville
Washington
- Central Washington Health Services Association d/b/a Confluence Health — Wenatchee
View the official record on ClinicalTrials.gov →
Follow this trial
Get an email when our monthly digest covers enrollment changes and results for trials like this one.
Newsletter signup launches soon. (Site owner: set PUBLIC_BUTTONDOWN_USERNAME in
.env to activate this form.)